08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On June 13, 2019, the U.S. Department of the Treasury, Department of Labor, and Department of Health...
Read More >
As reported by Hotel News Resource, the number of hotel rooms under construction in the United State...
Read More >
Gathering clouds – flawed investigation made dismissal unfair - In Sunshine Hotel Ltd t/a Palm Cou...
Read More >
Alternative Technical Concepts (ATCs) are an important tool that government agencies use, and privat...
Read More >
On January 7, 2020, the U.S. Department of Labor’s Wage and Hour Division (WHD) issued three opinio...
Read More >
On Tuesday, President Trump formally nominated Eugene Scalia to serve as Secretary of Labor. Gene S...
Read More >